Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07408869
NCT07408869WithdrawnPhase 1

A Phase 1b, Open-Label Study Evaluating the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Cizutamig in IgE Mediated Diseases

Candid Therapeutics1 site in 1 country20 target enrollmentStarted: April 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Interventions

Trial Snapshot

Phase
Phase 1
Status
Withdrawn
Sponsor
Enrollment
20
Locations
1
Primary Endpoint
To evaluate the ability of cizutamig to reduce IgE levels
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.

Detailed Description

This is a Phase 1b, open-label study evaluating the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Sequential
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient meets at least one of the following:
  • •History of documented (skin prick test, in vitro testing, or food challenge), ongoing, IgE-mediated allergy to food (eg, peanut, hazelnut, walnut, cashew, milk, egg/egg white, soy, wheat, sesame, cod, salmon, tuna, lobster, crab and/or shrimp) with Screening total IgE ≥ 400 IU/mL
  • •Diagnosis of chronic rhinosinusitis with Screening total IgE > ULN
  • •Diagnosis of allergic rhinitis with Screening total IgE > ULN
  • •Diagnosis of asthma and classified as well controlled per 2024 Global Initiative for Asthma guidelines with Screening total IgE > ULN
  • •Diagnosis of chronic spontaneous urticaria with symptoms (eg, wheals or angioedema) for at least 6 weeks any time prior to screening and Screening total IgE > ULN
  • •Diagnosis of atopic dermatitis that has been present for at least 6 months before the screening visit and with Screening total IgE > ULN
  • •Agree to the use of highly effective contraception

Exclusion Criteria

  • •Elevated IgE levels for reasons other than the IgE mediated diseases
  • •Planned ingestion of food items to which they are allergic for the duration of the study (for food allergy patients)
  • •Current use of any allergen immunotherapy.
  • •Individuals whose allergen exposures in their home and/or work environments may be expected to change significantly during the trial period
  • •Inadequate clinical laboratory parameters at Screening
  • •Receipt of or inability to discontinue any excluded therapies
  • •Individuals who will decline blood products
  • •Active infection
  • •Serious mental illness, drug or alcohol abuse, dementia, or other condition that impair ability to sign ICF
  • •Individuals who are hypersensitive to intravenous immunoglobulin (IVIg)
  • •History of primary immunodeficiency
  • •History of CNS disease
  • •History of poorly controlled diabetes, chronic kidney disease, chronic pulmonary disease, uncontrolled cardiovascular disease, history of malignancy within 5 years
  • •History of severe allergic or anaphylactic reactions to mAb therapy (or recombination antibody-related fusion proteins) or any constituents of study drug
  • •Major surgery requiring the use of general anesthesia within 12 weeks prior to Screening or planned or expected major surgery during the study period
  • •Blood donation or significant blood loss within 30 days prior to screening
  • •Individuals considered to be part of a vulnerable population (eg, incarceration)
  • •Individuals that in the opinion of the Investigator, are not suitable for participation in the trial
  • •Inability to comply with protocol-mandated requirements
  • •A history of severe allergic or anaphylactic reactions related to the underlying IgE mediated disease

Arms & Interventions

cizutamig (multiple dose)

Experimental

cizutamig will be dosed subcutaneously according to the cohort assignment

Intervention: Cizutamig (Biological)

cizutamig (single dose)

Experimental

cizutamig will be dosed subcutaneously according to the cohort assignment

Intervention: Cizutamig (Biological)

Outcomes

Primary Outcomes

To evaluate the ability of cizutamig to reduce IgE levels

Time Frame: Baseline to Week 12

Change from baseline in serum IgE

Secondary Outcomes

  • Incidence and severity of treatment-emergent adverse events through end of study(Baseline to Week 24)
  • PK parameters: Cmax(Baseline to 24 Weeks)
  • PK parameters: Tmax(Baseline to Week 24)
  • PK parameters: AUC(Baseline to 24 Weeks)
  • PK Parameter: CL(Baseline to 24 Weeks)
  • PK Parameters: Vd(Baseline to 24 Weeks)
  • PK Parameters: t1/2(Baseline to 24 Weeks)
  • Anti-drug antibodies (ADAs)(Baseline to 24 Weeks)
  • Changes in body temperature(Baseline to 24 Weeks)
  • Changes to blood pressure(Baseline to 24 Weeks)
  • Changes in heart rate(Baseline to 24 Weeks)
  • Changes to respiratory rate(Baseline to 24 Weeks)
  • Changes to pulse oximetry(Baseline to 24 Weeks)
  • Changes in ECG parameters: QRS interval(Baseline to 24 Weeks)
  • Changes in ECG parameters: PR interval(Baseline to 24 Weeks)
  • Changes in ECG parameters: QTcB(Baseline to 24 Weeks)
  • Changes in ECG parameters: QTcF(Baseline to 24 Weeks)
  • Changes in ECG parameters: QT interval(Baseline to 24 Weeks)
  • Changes in ECG parameters: RR(Baseline to 24 Weeks)
  • Changes from baseline in safety laboratory assessments through end of study: serum chemistry(Baseline to 24 Weeks)
  • Changes from baseline in Red Blood Cell count(Baseline to 24 Weeks)
  • Changes from baseline in White Blood Cell count(Baseline to 24 Weeks)
  • Changes from baseline in Platelets(Baseline to 24 Weeks)
  • Changes from baseline in Hematocrit(Baseline to 24 Weeks)
  • Changes from baseline in Hemoglobin(Baseline to 24 Weeks)
  • Frequency and percentage of anti-drug antibodies (ADAs)(Baseline to 24 Weeks)

Investigators

Sponsor
Candid Therapeutics
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
2024-513708-33-00Sutro Biopharma Inc.20
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
NCT07354724Denali Therapeutics Inc.32
Recruiting
Phase 2
Clinical trial of MDNA11 (investigational drug) administered alone or in combination with pembrolizumab (immune checkpoint inhibitor) in Patients with Advanced Solid Tumors
2023-507536-21-00Medicenna Therapeutics Inc.50
Recruiting
Phase 2
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
NCT07347249Hemab ApS18
Recruiting
Phase 1
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
NCT07328217Dizal Pharmaceuticals203